Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January

GlaxoSmithKline plc Sponsored ADR -1.36% Post
Pfizer Inc. -0.85% Post
Sanofi Sponsored ADR -0.95% Post
Takeda Pharmaceutical Company Limited +0.38% Post

GlaxoSmithKline plc Sponsored ADR

GSK

39.95

40.00

-1.36%

+0.13% Post

Pfizer Inc.

PFE

25.69

25.71

-0.85%

+0.08% Post

Sanofi Sponsored ADR

SNY

45.80

45.80

-0.95%

0.00% Post

Takeda Pharmaceutical Company Limited

TAK

13.23

13.24

+0.38%

+0.08% Post

Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on more than 500 drugs in the U.S. in early January.

Companies including Pfizer Inc (NYSE:PFE), Sanofi SA (NASDAQ: SNY), and Takeda Pharmaceutical Co Ltd (NYSE:TAK) are expected to participate in the move that comes as part of the pharmaceutical industry's preparation for the forthcoming publication of significantly discounted prices for ten high-cost drugs by the Biden Administration in September

Additionally, the industry faces challenges posed by elevated inflation rates and escalating manufacturing costs.

Healthcare research firm 3 Axis Advisors' data indicates that amidst these developments, three companies, including GSK Plc (NYSE:GSK), are anticipated to decrease prices on at least 15 unique drugs in January, Reuters reported. 

This follows GlaxoSmithKline's recent announcement of price reductions on specific asthma, herpes, and anti-epileptic drugs slated for 2024.

The evolving landscape also aligns with efforts by various companies earlier this year to decrease insulin prices to avoid penalties outlined in the 2021 American Rescue Plan Act

Despite heightened inflation rates, drugmakers have generally restrained price increases to 10% or lower, steering away from the sharp hikes seen in the past. 

Antonio Ciaccia, President of 3 Axis, anticipates significant impacts on former blockbuster insulin drugs due to the prevailing policy changes.

The adjustments in drug prices primarily affect list prices, excluding rebates to pharmacy benefit managers and other discounts. Despite concerns and changing dynamics, drugmakers have maintained a consistent median price increase of around 5% since 2019, indicating a cautious approach.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Image by Arek Socha from Pixabay

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via